AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,374,421 | -2.7% | 1,182,107 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $14,774,316 | +13.7% | 1,176,299 | +0.4% | 0.00% | 0.0% |
| Q1 2023 | $12,990,328 | -10.7% | 1,171,355 | -1.7% | 0.00% | 0.0% |
| Q4 2022 | $14,552,769 | +13.4% | 1,191,873 | -3.1% | 0.00% | 0.0% |
| Q3 2022 | $12,837,000 | +1.8% | 1,229,564 | +4.8% | 0.00% | 0.0% |
| Q2 2022 | $12,606,000 | +17.9% | 1,173,726 | +3.9% | 0.00% | +50.0% |
| Q1 2022 | $10,696,000 | -17.9% | 1,129,504 | +0.2% | 0.00% | 0.0% |
| Q4 2021 | $13,024,000 | +21.8% | 1,127,518 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $10,695,000 | +0.5% | 1,119,878 | +1.5% | 0.00% | 0.0% |
| Q2 2021 | $10,639,000 | +2.8% | 1,103,592 | +5.4% | 0.00% | 0.0% |
| Q1 2021 | $10,345,000 | -81.4% | 1,047,164 | -56.4% | 0.00% | -83.3% |
| Q4 2020 | $55,519,000 | +73.6% | 2,404,484 | +6.1% | 0.01% | +50.0% |
| Q3 2020 | $31,985,000 | -6.8% | 2,265,214 | -0.5% | 0.01% | -11.1% |
| Q2 2020 | $34,332,000 | +69.1% | 2,276,687 | +3.6% | 0.01% | +28.6% |
| Q1 2020 | $20,299,000 | -7.6% | 2,196,853 | -2.6% | 0.01% | +16.7% |
| Q4 2019 | $21,965,000 | +25.8% | 2,255,081 | +3.6% | 0.01% | +20.0% |
| Q3 2019 | $17,454,000 | -34.5% | 2,176,361 | +2.0% | 0.01% | -28.6% |
| Q2 2019 | $26,628,000 | -3.4% | 2,133,625 | +5.3% | 0.01% | -12.5% |
| Q1 2019 | $27,567,000 | +39.7% | 2,027,093 | -1.6% | 0.01% | +33.3% |
| Q4 2018 | $19,729,000 | -20.0% | 2,059,353 | +0.9% | 0.01% | 0.0% |
| Q3 2018 | $24,668,000 | -22.8% | 2,040,353 | -0.3% | 0.01% | -33.3% |
| Q2 2018 | $31,970,000 | +4.2% | 2,046,768 | +0.3% | 0.01% | +12.5% |
| Q1 2018 | $30,681,000 | +142.4% | 2,039,837 | +131.9% | 0.01% | +166.7% |
| Q4 2017 | $12,655,000 | -2.2% | 879,536 | +2.5% | 0.00% | -25.0% |
| Q3 2017 | $12,941,000 | +104.3% | 858,184 | +36.4% | 0.00% | +100.0% |
| Q2 2017 | $6,334,000 | +32.1% | 629,086 | -6.5% | 0.00% | +100.0% |
| Q1 2017 | $4,794,000 | +61.4% | 672,463 | +12.5% | 0.00% | 0.0% |
| Q4 2016 | $2,971,000 | -31.6% | 597,763 | +1.8% | 0.00% | 0.0% |
| Q3 2016 | $4,345,000 | +22.6% | 587,202 | -9.6% | 0.00% | 0.0% |
| Q2 2016 | $3,545,000 | -22.6% | 649,235 | +19.8% | 0.00% | 0.0% |
| Q1 2016 | $4,580,000 | -14.0% | 542,020 | -1.3% | 0.00% | -50.0% |
| Q4 2015 | $5,327,000 | -34.3% | 549,126 | -5.3% | 0.00% | 0.0% |
| Q3 2015 | $8,111,000 | -1.5% | 579,743 | -0.4% | 0.00% | 0.0% |
| Q2 2015 | $8,234,000 | +209.0% | 581,953 | +137.6% | 0.00% | +100.0% |
| Q1 2015 | $2,665,000 | +20.0% | 244,962 | -8.2% | 0.00% | 0.0% |
| Q4 2014 | $2,220,000 | +104.8% | 266,773 | +46.4% | 0.00% | – |
| Q3 2014 | $1,084,000 | +185.3% | 182,229 | +59.9% | 0.00% | – |
| Q2 2014 | $380,000 | +22.6% | 113,988 | -23.9% | 0.00% | – |
| Q1 2014 | $310,000 | -12.9% | 149,822 | -1.2% | 0.00% | – |
| Q4 2013 | $356,000 | -47.8% | 151,580 | -48.5% | 0.00% | – |
| Q3 2013 | $682,000 | +97.7% | 294,384 | +98.8% | 0.00% | – |
| Q2 2013 | $345,000 | – | 148,061 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |